{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:13:53Z","timestamp":1788480833487,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>In the majority of approaches, detoxification of patients with benzodiazepine (BZD) addiction is preceded by conversion to long-acting BZDs. Resulting BZD accumulation, however, is neither monitored nor prevented. An unrecognized shift of the key low-concentration phase beyond the nominal treatment period may underlie delayed unassisted crises and treatment failures. This open, single-arm, semi-naturalistic study examines the anti-accumulation paradigm to minimize the high-concentration treatment phase and to regain time for medical assistance during the low-concentration phase.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In 133 of 165 patients with BZD dependency, after conversion to diazepam by titration up to the satiation state, the loading dose and satiating concentration were recorded. The subsequent anti-accumulation procedure consisted of aggressive daily dose reductions under laboratory feedback (serum BZD concentration, radioimmunoassay) until accumulation stopped. The final overaccumulation ratio (OA) and maintenance-dose\/loading-dose ratio (MTN) were estimated. The post-conversion peak-concentration\/loading-dose ratio was illustratively compared with the concentration\/dose ratio in 32 long-term diazepam users demonstrating the natural plateau.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Despite gender- and age-related differences in loading and maintenance doses and in satiating and peak concentrations (higher in younger and male patients), their quotients remained similar. The MTN ratio had an average value of 0.29 and a median value of 0.25, with OA ratios of 1.54 and 1.39, respectively. The concentration\/dose ratio was approximately 3 times lower than that in regular diazepam users. With effective elimination starting (on average) from the 6th day, the treatment, including post-elimination recovery, lasted on average 52\u00a0days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The MTN values show how harmfully popular tapering schedules intensify and extend the high-concentration stage during alleged detoxification, leading to unrecognized delays in elimination, and delayed withdrawal crises. The common errors are discussed. An individual MTN, estimated from laboratory feedback (the anti-accumulation paradigm), expeditiously moves patients to the onset of actual detoxification. This action regains time to maintain medical assistance until treatment is properly completed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03388-x","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T11:05:32Z","timestamp":1663412732000},"page":"1833-1841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-1901","authenticated-orcid":false,"given":"Anna","family":"Basi\u0144ska-Szafra\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"issue":"1\u20132","key":"3388_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0740-5472(91)90023-4","volume":"8","author":"H Ashton","year":"1991","unstructured":"Ashton H (1991) Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 8(1\u20132):19\u201328. https:\/\/doi.org\/10.1016\/0740-5472(91)90023-4","journal-title":"J Subst Abuse Treat"},{"key":"3388_CR2","unstructured":"Center for Substance Abuse Treatment (2010) Protracted withdrawal. Substance Abuse Treatment Advisory. 9(1).\u00a0https:\/\/store.samhsa.gov\/product\/protracted-withdrawal\/SMA10-4554. Accessed\u00a015 Dec\u00a02020"},{"issue":"3","key":"3388_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/jcpt.13333","volume":"46","author":"JV Pergolizzi Jr","year":"2021","unstructured":"Pergolizzi JV Jr, LeQuang JA, Raffa RB (2021) Benzodiazepines: thinking outside the black box. J Clin Pharm Ther 46(3):554\u2013559. https:\/\/doi.org\/10.1111\/jcpt.13333","journal-title":"J Clin Pharm Ther"},{"key":"3388_CR4","doi-asserted-by":"publisher","unstructured":"LaCorte S (2018) How chronic administration of benzodiazepines leads to unexplained chronic illnesses: a hypothesis.\u00a0Med. Hypotheses\u00a0118:59\u201367. https:\/\/doi.org\/10.1016\/j.mehy.2018.06.019. Epub 20 Jun\u00a02018","DOI":"10.1016\/j.mehy.2018.06.019"},{"key":"3388_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00228-021-03205-x","volume":"78","author":"A Basi\u0144ska-Szafra\u0144ska","year":"2022","unstructured":"Basi\u0144ska-Szafra\u0144ska A (2022) Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking. Eur J Clin Pharmacol 78:101\u2013110. https:\/\/doi.org\/10.1007\/s00228-021-03205-x","journal-title":"Eur J Clin Pharmacol"},{"issue":"6292","key":"3388_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bmj.283.6292.643","volume":"283","author":"H P\u00e9tursson","year":"1981","unstructured":"P\u00e9tursson H, Lader MH (1981) Withdrawal from long-term benzodiazepine treatment BMJ (Br Med J) 283(6292):643\u2013645. https:\/\/doi.org\/10.1136\/bmj.283.6292.643","journal-title":"Withdrawal from long-term benzodiazepine treatment BMJ (Br Med J)"},{"issue":"6424","key":"3388_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/bmj.288.6424.1135","volume":"288","author":"H Ashton","year":"1984","unstructured":"Ashton H (1984) Benzodiazepine withdrawal: an unfinished story BMJ (Br Med J) 288(6424):1135\u20131140. https:\/\/doi.org\/10.1136\/bmj.288.6424.1135","journal-title":"Benzodiazepine withdrawal: an unfinished story BMJ (Br Med J)"},{"key":"3388_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0376-8716(91)90049-5","volume":"29","author":"PM Brenner","year":"1991","unstructured":"Brenner PM, Wolf B, Rechlin T, Kauert G, R\u00fcther E, Hippius H (1991) Benzodiazepine dependence: detoxification under standardized conditions. Drug Alcohol Depend 29:195\u2013204","journal-title":"Drug Alcohol Depend"},{"key":"3388_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1124\/jpet.111.183285","volume":"339","author":"MM Reidenberg","year":"2011","unstructured":"Reidenberg MM (2011) Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 339:324\u2013328. https:\/\/doi.org\/10.1124\/jpet.111.183285","journal-title":"J Pharmacol Exp Ther"},{"key":"3388_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00228-020-03048-y","volume":"77","author":"A Basi\u0144ska-Szafra\u0144ska","year":"2021","unstructured":"Basi\u0144ska-Szafra\u0144ska A (2021) Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines. The rationale for serum BZD concentration monitoring. Eur J Clin Pharmacol 77:795\u2013808. https:\/\/doi.org\/10.1007\/s00228-020-03048-y","journal-title":"Eur J Clin Pharmacol"},{"key":"3388_CR11","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group (2017) Benzodiazepines and z-drugs. In: Drug misuse and dependence: UK guidelines on clinical management. London,\u00a0Department of Health (Chapter 4.10.1, p 121). https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf. Accessed 15\u00a0Dec\u00a02020"},{"key":"3388_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","volume":"18","author":"H Ashton","year":"2005","unstructured":"Ashton H (2005) The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatr 18:249\u2013255","journal-title":"Curr Opin Psychiatr"},{"key":"3388_CR13","unstructured":"Ashton CH (2007) Benzodiazepines equivalence table (revised version). https:\/\/www.benzo.org.uk\/bzequiv.htm. Accessed 15 Dec 2020"},{"key":"3388_CR14","unstructured":"Taylor DM, Barnes TRE, Young AH (2018) Addictions and substance misuse. Benzodiazepine misuse. In: The Maudsley Prescribing Guidelines in Psychiatry, 13th edn. Wiley, Hoboken, NJ, pp 445\u2013447"},{"issue":"1","key":"3388_CR15","first-page":"139","volume":"58","author":"NS Miller","year":"1998","unstructured":"Miller NS, Gold MS (1998) Management of withdrawal syndromes and relapse prevention in drug and alcohol dependence. Am Fam Physician 58(1):139\u2013146","journal-title":"Am Fam Physician"},{"issue":"4","key":"3388_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/clpt.1984.214","volume":"36","author":"M Harrison","year":"1984","unstructured":"Harrison M, Busto U, Naranjo CA, Kaplan HL, Sellers EM (1984) Diazepam tapering in detoxification for high-dose benzodiazepine abuse. Clin Pharmacol Ther 36(4):527\u2013533","journal-title":"Clin Pharmacol Ther"},{"key":"3388_CR17","unstructured":"Taylor DM, Barnes TRE, Young AH (2018) Pharmacokinetics. Plasma level monitoring of psychotropic drugs. In: The Maudsley Prescribing Guidelines in Psychiatry, 13th edn. Wiley, Hoboken, NJ, pp 731\u2013732"},{"key":"3388_CR18","unstructured":"Ashton CH (2002) Slow withdrawal schedules. In: Benzodiazepines: how they work and how to withdraw. The Ashton manual (rev. version 2013). https:\/\/www.benzo.org.uk\/manual\/bzsched.htm. Accessed\u00a015 Dec\u00a02020"},{"key":"3388_CR19","first-page":"57","volume-title":"The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research","author":"World Health Organization","year":"1993","unstructured":"World Health Organization (1993) The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. World Health Organization, Geneva, p 57"},{"issue":"6","key":"3388_CR20","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/clpt.1983.256","volume":"34","author":"EM Sellers","year":"1983","unstructured":"Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K (1983) Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther 34(6):822\u2013826. https:\/\/doi.org\/10.1038\/clpt.1983.256","journal-title":"Clin Pharmacol Ther"},{"key":"3388_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00004714-198912000-00005","volume":"9","author":"AI Busto","year":"1989","unstructured":"Busto AI, Sykora K, Sellers E (1989) A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 9:412\u2013416","journal-title":"J Clin Psychopharmacol"},{"key":"3388_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2165\/00003088-197803010-00005","volume":"3","author":"M Mandelli","year":"1978","unstructured":"Mandelli M, Tognoni G, Garattini S (1978) Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 3:72\u201391","journal-title":"Clin Pharmacokinet"},{"key":"3388_CR23","unstructured":"Roche Diagnostics (2015) Serum Benzodiazepines (SBENZ) #20766690322, Method sheet v.8. Roche Diagnostics GmbH, Mannheim.\u00a0https:\/\/pim-eservices.roche.com\/LifeScience\/Document\/2ca042f2-2d7f-e511-bbab-00215a9b3428. Accessed\u00a015 Jan\u00a02021"},{"key":"3388_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/09595230100100615","volume":"22","author":"C McGregor","year":"2003","unstructured":"McGregor C, Machin A, White JM (2003) In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug and Alcohol Rev 22:175\u2013180","journal-title":"Drug and Alcohol Rev"},{"key":"3388_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1192\/bjp.189.3.213","volume":"189","author":"RC Voshaar","year":"2006","unstructured":"Voshaar RC, Couv\u00e9e HL, van Balkom AJ, Mulder PG, Zitman FG (2006) Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry 189:213\u2013220. https:\/\/doi.org\/10.1192\/bjp.189.3.213","journal-title":"Br J Psychiatry"},{"key":"3388_CR26","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","volume":"106","author":"M Lader","year":"2011","unstructured":"Lader M (2011) Benzodiazepines revisited - will we ever learn? Addiction 106:2086\u20132109. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03563.x","journal-title":"Addiction"},{"key":"3388_CR27","unstructured":"Statsoft Inc (2017) Statistica 13.3.0.\u00a0https:\/\/www.statsoft.pl\/statistica_13_3\/. Accessed 15 Dec\u00a02020"},{"issue":"2","key":"3388_CR28","first-page":"113","volume":"139","author":"EM Sellers","year":"1988","unstructured":"Sellers EM (1988) Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. CMAJ 139(2):113\u2013120","journal-title":"CMAJ"},{"issue":"01\/02","key":"3388_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51(01\/02):9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"key":"3388_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-015-0019-8","volume":"16","author":"AS Pollmann","year":"2015","unstructured":"Pollmann AS, Murphy AL, Bergman JC, Gardner DM (2015) Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 16:19. https:\/\/doi.org\/10.1186\/s40360-015-0019-8","journal-title":"BMC Pharmacol Toxicol"},{"key":"3388_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/BF00562659","volume":"8","author":"M Eichelbaum","year":"1975","unstructured":"Eichelbaum M, Ekbom B, Bertilsson L et al (1975) Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 8:337\u2013341","journal-title":"Eur J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03388-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03388-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T07:09:13Z","timestamp":1665126553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03388-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["3388"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03388-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The methodology of the study was approved by the Bioethical Committee at the Institute of Psychiatry and Neurology of Warsaw (Ethics approval no 18\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}